Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

New Epistem chief to start six weeks early

David Budd will now take over on 1 March instead of the middle of April as previously anticipated.
New Epistem chief to start six weeks early
Epistem revealed yesterday its genedrive diagnostic test had been cleared for European clinical trials in Hepatitis C

Epistem Holdings' (LON:EHP) new chief executive is to join six weeks earlier than planned.

David Budd will now take over on 1 March instead of the middle of April as previously anticipated.

Budd has more than 20 years of international commercial and operational experience in diagnostics and medical devices, especially in the molecular field.

He joins from Danaher subsidiary Leica Biosystems where he was last post was general manager of Leica Biosystems Amsterdam.

At Leica Biosystems Newcastle, he had global responsibility for marketing, market research and product launches for diagnostic tests.

Epistem revealed yesterday its genedrive diagnostic test had been cleared for European clinical trials in Hepatitis C (HCV) by the Institut Pasteur in Paris.

Genedrive was launched to test for TB in India last year.

Budd said: “I believe Genedrive is an outstanding molecular diagnostic system with significant near term commercial opportunities in tuberculosis testing and across a wide range of other applications in the future.”

PhilW.jpg
Why Invest In Epistem Holdings Plc? Read More Here

Register here to be notified of future EHP Company articles
View full EHP profile

Epistem Holdings Plc Timeline

Related Articles

Peanuts.jpg
March 08 2016
Not to be sneezed at: Allergy Therapeutics' ground-breaking allergy vaccines address several lucrative markets
immupharma-_kiss_pic_with_mum.png
March 01 2016
Lupuzor is not the only part of the Immupharma story and McCarthy plans also to raise the profile of the rest of the group's early stage pipeline in 2016.....
shutterstock_327930536.jpg
May 19 2016
Life sciences firm ValiRx is poised for a busy year ahead as it progresses its lead drugs...

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.